Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder

Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the relationship of its daily steady‐state exposure (C(av,ss)) to the probability of most frequent t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalovic, Bojan, Majid, Oneeb, Aluri, Jagadeesh, Landry, Ishani, Moline, Margaret, Hussein, Ziad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689791/
https://www.ncbi.nlm.nih.gov/pubmed/32666570
http://dx.doi.org/10.1002/jcph.1683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689791/
https://www.ncbi.nlm.nih.gov/pubmed/32666570
http://dx.doi.org/10.1002/jcph.1683

Ejemplares similares